Homocysteine is a naturally occurring amino acid in the body, but elevated levels are a red flag. High homocysteine is linked to heart, brain, and vascular health issues—including increased risk of stroke and cognitive decline. OPTI + HOMOCYSTEINE™ is designed to help your body metabolize and regulate homocysteine effectively with targeted B vitamins and key methyl donors.

OPTI + HOMOCYSTEINE™ uses activated B vitamins like methylfolate (5-MTHF), B6 (P5P), and methylated B12—forms your body can use right away, especially if you have MTHFR gene variations. These nutrients help convert homocysteine into methionine, a process essential for detoxification, methylation, and cardiovascular health.

Most B-complexes use cheaper, inactive forms of B vitamins—like folic acid instead of methylfolate, or cyanocobalamin instead of methylcobalamin.
OPTI + HOMOCYSTEINE™ was specifically formulated to support homocysteine regulation using only the active, physician-preferred forms your body recognizes and absorbs best.

Everyone’s biochemistry is different, but many people see improvements in blood homocysteine levels within 6–12 weeks of consistent use. For best results, pair this with regular blood testing and a healthy diet low in processed foods.

Anyone with elevated homocysteine levels, a family history of heart or brain conditions, or known MTHFR gene mutations can benefit. It’s also ideal for those looking to support healthy methylation, detox, and inflammation balance. Always consult your healthcare provider before starting if you’re pregnant, nursing, or on medication.

Yes—when used as directed, OPTI + HOMOCYSTEINE™ is safe for daily, long-term support. It's gentle on the stomach, free from unnecessary fillers, and third-party tested for purity and potency. This formula is designed for daily use to help keep homocysteine levels in check year-round.

• Homocysteine Studies Collaboration. Homocysteine and risk of ischemic heart disease and stroke: a meta‑analysis. JAMA. 2002;288(16):2015–2022. https://pubmed.ncbi.nlm.nih.gov/12387654/
• Lonn E, Yusuf S, Arnold MJ, et al. Homocysteine lowering with folic acid and B vitamins in vascular disease (HOPE‑2). N Engl J Med. 2006;354(15):1567–1577. https://pubmed.ncbi.nlm.nih.gov/16531613/
• Clarke R, Halsey J, Lewington S, et al. Effects of lowering homocysteine levels with B vitamins on cardiovascular disease, cancer, and cause‑specific mortality: meta‑analysis. BMJ. 2010;340:c2197. https://pubmed.ncbi.nlm.nih.gov/20472638/
• Martí-Carvajal AJ, Solà I, Lathyris D, et al. Homocysteine-lowering interventions for preventing cardiovascular events. Cochrane Database Syst Rev. 2017;8:CD006612. https://pubmed.ncbi.nlm.nih.gov/28836225/
• Obeid R, Herrmann W. Homocysteine and lipids: S-adenosyl methionine and methylation reactions. Clin Chem Lab Med. 2005;43(10):1074–1081. https://pubmed.ncbi.nlm.nih.gov/16232007/
• Refsum H, Ueland PM, Nygård O, Vollset SE. Homocysteine and cardiovascular disease. Annu Rev Med. 1998;49:31–62. https://pubmed.ncbi.nlm.nih.gov/9509248/
• van Guldener C, Stehouwer CD. Homocysteine-lowering treatment: an overview. Expert Opin Pharmacother. 2001;2(9):1449–1460. https://pubmed.ncbi.nlm.nih.gov/11585013/
• Selhub J. Homocysteine metabolism. Annu Rev Nutr. 1999;19:217–246. https://pubmed.ncbi.nlm.nih.gov/10448523/
• Clarke R, Daly L, Robinson K, et al. Hyperhomocysteinemia: an independent risk factor for vascular disease. N Engl J Med. 1991;324(17):1149–1155. https://pubmed.ncbi.nlm.nih.gov/2011158/
• O’Leary F, Samman S. Vitamin B12 in health and disease. Nutrients. 2010;2(3):299–316. https://pubmed.ncbi.nlm.nih.gov/22254022/